A Phase 2 Study of Tandutinib in Patients With Newly Diagnosed Acute Myelogenous Leukemia Who Are Considered Ineligible For or Who Decline Treatment With Standard Induction Therapy
Clinical trial NCT00297921 · WITHDRAWN
Trial details
- NCT number
- NCT00297921
- Sponsor
- Millennium Pharmaceuticals, Inc.
- Status
- WITHDRAWN
- Phase
- Phase 1, Phase 2
- Study type
- INTERVENTIONAL
- Enrollment
- 0
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.